Novavax is a global clinical-stage biopharmaceutical company engaged in creating vaccines to address a wide range of infectious diseases throughout the world. Using innovative technology and new efficient manufacturing approaches, Novavax produces potent vaccine candidates with the goal of enabling countries to be well-prepared for and more effectively responsive to rapidly spreading infections. Committed to using its technology platforms to create location-specific vaccine solutions, Novavax is involved in a number of international partnerships. For more information, visit the company’s Web site at www.novavax.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: